| News for nuclear medicine and molecular imaging professionals |  |
| |
|
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple
internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher.
The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may
be directed to SmartBrief at snmmi@smartbrief.com.
|
- FDG-PET sheds light on survival in non-small cell lung cancer
 Positive results on an FDG-PET scan may indicate poorer survival in patients with early-stage non-small cell lung cancer, according to findings presented at a cancer research meeting. Patients with the positive PET scan showed a median five-year survival of 67%, while survival for those with negative results was 80%. The method may help determine which patients should have adjuvant chemotherapy, researchers said. MedPage Today (free registration)
(4/10)
 | Online Grad Programs from Hopkins Public Health
Advance your career with a graduate degree or certificate from the Johns Hopkins Bloomberg School of Public Health. Our Online Programs for Applied Learning focus on the burgeoning fields of patient safety and healthcare quality, population health management and spatial analysis.
Learn More |
| |
|
|  |
| Clinical News & Research
|  |  |
|
- PET/CT helps gauge patient response to neoadjuvant chemotherapy
A study presented at a radiology meeting found that FDG-PET/CT has the potential to predict patient response following neoadjuvant chemotherapy for breast cancer. Researchers said the results suggest the assessment could be useful for guiding treatment decisions. The researchers used Sinn scores and two algorithms to measure patient response. An 88% change in maximum standardized uptake value is the appropriate cutoff to distinguish lesions that respond to treatment, they reported. AuntMinnie.com (free registration)
(4/10)
| Industry Report
| | |
|
- Cell>Point reports promising findings for 99mTc-EC-G
Radiopharmaceutical firm Cell>Point said findings from Phase I and IIa trials were promising for its technetium-99m-labeled ethylenedicysteine-glucosamine, an imaging agent used in diagnosing coronary artery disease. The company is planning a Phase IIb study to assess the diagnostic accuracy of the agent in identifying ischemia in patients at rest who have coronary artery disease. AuntMinnie.com (free registration)
(4/10)
| News from the Field
| | |
|
- AHRA backs breast density advocacy effort
AHRA: The Association for Medical Imaging Management has announced its support for the Are You Dense Advocacy group, which aims to standardize the notification of breast density information. Fifteen breast density measures have been introduced this year in states, and a federal breast density bill is also expected to be revived, according to AHRA. AuntMinnie.com (free registration)
(4/10)
| International Developments
| | |
|
- Researchers create gold nanoparticles for biokinetic studies
Researchers in Germany have developed radiolabeled gold nanoparticles for application in studies designed to evaluate how the particles function in biological systems. The gold radioisotope has a 186-day half-life, which makes it useful for long-term biokinetic studies, according to the report published in the Journal of Nanoparticle Research. Researchers said the nanoparticles can be stable for several hours, meaning they are useful for risk assessments. ChemicalWatch.com (free content)
(4/10)
| Health Policy
| | |
|
- FDA seeks input on effects of extreme weather on medtech
The FDA is accepting comments through May 10 on the possible effects of natural disasters and extreme weather on the following: medical devices already being used in patient care; unused devices, parts or accessories; and manufacturing plants. A public meeting will also be held today to explore ways to better address manufacturing challenges tied to extreme weather. Clinica (subscription required)
(4/8)
| Advancing Health Care
| | |
|
| From SNMMI
| | |
|
- Now available! Nuclear Medicine Review Course online
Getting ready to take the board exam? SNMMI's Nuclear Medicine Review Course consists of 14 lectures by world-renowned experts lecturing on the most critical topics in clinical nuclear medicine, including Physics & Instrumentation Pediatric Review, Endocrine Review PET/CT, Review of Gastrointestinal & Abdominal Imaging, Pulmonary Review, Immunotherapy Review, Review of Genitourinary System, Skeletal Review Tumor & Abscess Review, Review NRC Regulations Central Nervous System Review, and Cardiac Review Case Review. Get started today.
| SmartQuote
| | |
|
 | To live is so startling it leaves little time for anything else."
--Emily Dickinson,
American poet
|
| |
| |
|
Read more at
SmartBrief.com |
|
|
|
| |
| |
| | Recent
SNMMI SmartBrief Issues:
- Wednesday, April 10, 2013
- Tuesday, April 09, 2013
- Monday, April 08, 2013
- Friday, April 05, 2013
- Thursday, April 04, 2013
| | | Lead Editor:
Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2013 SmartBrief, Inc.®
Legal Information |
|
